JP2004532877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532877A5 JP2004532877A5 JP2003500091A JP2003500091A JP2004532877A5 JP 2004532877 A5 JP2004532877 A5 JP 2004532877A5 JP 2003500091 A JP2003500091 A JP 2003500091A JP 2003500091 A JP2003500091 A JP 2003500091A JP 2004532877 A5 JP2004532877 A5 JP 2004532877A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- prevention
- treatment
- disorder
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010002855 Anxiety Diseases 0.000 claims 2
- 206010057666 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010004939 Bipolar I disease Diseases 0.000 claims 2
- 206010004938 Bipolar disease Diseases 0.000 claims 2
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 201000001971 Huntington's disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 229960002715 Nicotine Drugs 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 210000000225 Synapses Anatomy 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 206010044126 Tourette's disease Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000001713 cholinergic Effects 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 2
- 229930015196 nicotine Natural products 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 201000006704 ulcerative colitis Diseases 0.000 claims 2
- 206010061284 Mental disease Diseases 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- UMULYXKQASVZSU-TYJDENFWSA-N C1OC=CC1c(cn1)cc(C2)c1O[C@@]21C(CC2)CCN2C1 Chemical compound C1OC=CC1c(cn1)cc(C2)c1O[C@@]21C(CC2)CCN2C1 UMULYXKQASVZSU-TYJDENFWSA-N 0.000 description 1
Claims (11)
- 式：
- 請求項１に記載の化合物、および薬学的に許容しうる希釈剤または担体を含む医薬組成物。
- α７ニコチン性受容体の活性化が有効なヒトの疾病または症状の治療または予防に使用するための請求項２に記載の医薬組成物。
- 精神異常または知能低下障害の治療または予防に使用するための請求項２に記載の医薬組成物。
- アルツハイマー病、学習欠損、認知欠損、注意欠損、記憶喪失、注意欠損多動性障害、不安症、統合失調症、または躁病若しくは躁鬱病、パーキンソン病、ハンチントン病、トゥーレット症候群、コリン作用性シナプスが欠失している神経変性障害、時差ぼけ、禁煙、ニコチン含有製品への曝露によるニコチン中毒、疼痛、および潰瘍性大腸炎の治療または予防に使用するための請求項２に記載の医薬組成物。
- α７ニコチン性受容体の活性化が有効なヒトの疾病または症状の治療または予防のための薬剤の製造における請求項１に記載の化合物の使用。
- 精神異常または知能低下障害の治療または予防のための薬剤の製造における請求項１に記載の化合物の使用。
- 症状または障害がアルツハイマー病、学習欠損、認知欠損、注意欠損、記憶喪失、注意欠損多動性障害である請求項７に記載の使用。
- 障害が不安症、統合失調症、または躁病若しくは躁鬱病である請求項７に記載の使用。
- 障害がパーキンソン病、ハンチントン病、トゥーレット症候群、またはコリン作用性シナプスが欠失している神経変性障害である請求項７に記載の使用。
- 時差ぼけ、禁煙、ニコチン含有製品への曝露によるニコチン中毒、疼痛、および潰瘍性大腸炎の治療または予防のための薬剤の製造における請求項１に記載の化合物の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29520601P | 2001-06-01 | 2001-06-01 | |
| PCT/SE2002/001031 WO2002096912A1 (en) | 2001-06-01 | 2002-05-29 | Novel ligand for nicotinic acetylcholine receptors useful in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532877A JP2004532877A (ja) | 2004-10-28 |
| JP2004532877A5 true JP2004532877A5 (ja) | 2006-01-05 |
Family
ID=23136711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500091A Pending JP2004532877A (ja) | 2001-06-01 | 2002-05-29 | 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1397366B1 (ja) |
| JP (1) | JP2004532877A (ja) |
| KR (1) | KR20040003021A (ja) |
| CN (1) | CN1294136C (ja) |
| AT (1) | ATE353332T1 (ja) |
| BR (1) | BR0210075A (ja) |
| CA (1) | CA2455341A1 (ja) |
| DE (1) | DE60218032T2 (ja) |
| DK (1) | DK1397366T3 (ja) |
| ES (1) | ES2280538T3 (ja) |
| HK (1) | HK1063787A1 (ja) |
| IL (1) | IL158735A0 (ja) |
| MX (1) | MXPA03010996A (ja) |
| NO (1) | NO20035333D0 (ja) |
| NZ (1) | NZ529426A (ja) |
| PT (1) | PT1397366E (ja) |
| SI (1) | SI1397366T1 (ja) |
| WO (1) | WO2002096912A1 (ja) |
| ZA (1) | ZA200308779B (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| WO2003087103A1 (en) | 2002-04-18 | 2003-10-23 | Astrazeneca Ab | Thienyl compounds |
| CA2482313A1 (en) | 2002-04-18 | 2003-10-23 | Astrazeneca Ab | Heterocyclic compounds |
| US7417049B2 (en) | 2002-04-18 | 2008-08-26 | Astrazeneca Ab | Furyl compounds |
| BRPI0415546A (pt) * | 2003-10-21 | 2006-12-26 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |
| TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| NZ590616A (en) | 2008-06-20 | 2012-09-28 | Astrazeneca Ab | Dibenzothiazepine derivatives and use thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| PL3029039T3 (pl) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| WO2014202999A1 (en) | 2013-06-21 | 2014-12-24 | Takeda Cambridge Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ500643A (en) * | 1997-05-30 | 2001-12-21 | Neurosearch As | Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
-
2002
- 2002-05-29 AT AT02731063T patent/ATE353332T1/de not_active IP Right Cessation
- 2002-05-29 CA CA002455341A patent/CA2455341A1/en not_active Abandoned
- 2002-05-29 BR BR0210075-4A patent/BR0210075A/pt not_active IP Right Cessation
- 2002-05-29 NZ NZ529426A patent/NZ529426A/en unknown
- 2002-05-29 DE DE60218032T patent/DE60218032T2/de not_active Expired - Fee Related
- 2002-05-29 JP JP2003500091A patent/JP2004532877A/ja active Pending
- 2002-05-29 CN CNB028110498A patent/CN1294136C/zh not_active Expired - Fee Related
- 2002-05-29 MX MXPA03010996A patent/MXPA03010996A/es active IP Right Grant
- 2002-05-29 IL IL15873502A patent/IL158735A0/xx unknown
- 2002-05-29 SI SI200230510T patent/SI1397366T1/sl unknown
- 2002-05-29 WO PCT/SE2002/001031 patent/WO2002096912A1/en active IP Right Grant
- 2002-05-29 EP EP02731063A patent/EP1397366B1/en not_active Expired - Lifetime
- 2002-05-29 DK DK02731063T patent/DK1397366T3/da active
- 2002-05-29 KR KR10-2003-7015462A patent/KR20040003021A/ko not_active Application Discontinuation
- 2002-05-29 ES ES02731063T patent/ES2280538T3/es not_active Expired - Lifetime
- 2002-05-29 PT PT02731063T patent/PT1397366E/pt unknown
-
2003
- 2003-11-11 ZA ZA200308779A patent/ZA200308779B/en unknown
- 2003-11-28 NO NO20035333A patent/NO20035333D0/no unknown
-
2004
- 2004-09-01 HK HK04106588A patent/HK1063787A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532877A5 (ja) | ||
| JP2003512374A5 (ja) | ||
| JP2003514818A5 (ja) | ||
| JP2007532637A5 (ja) | ||
| JP2003513073A5 (ja) | ||
| CN116056762A (zh) | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 | |
| JP2006507241A5 (ja) | ||
| TWI248932B (en) | Respiratory syncytial virus replication inhibitors | |
| JP2003513071A5 (ja) | ||
| DE60336890D1 (de) | Kondensierte pyridazinderivat-verbindungen und die verbindungen als wirkstoff enthaltende arzneimittel | |
| Mazurov et al. | 2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands | |
| JP2001510194A5 (ja) | ||
| HUP0401849A2 (hu) | Kinuklidinszármazékok, ezeket tartalmazó gyógyászati készítmények, továbbá ezek alkalmazása M2 és/vagy M3 muszkarin receptor inhibitorként | |
| JP2005534624A5 (ja) | ||
| JP2009504748A5 (ja) | ||
| JP2009537517A5 (ja) | ||
| JP5916746B2 (ja) | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 | |
| JP2010511668A5 (ja) | ||
| AR051919A1 (es) | Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto | |
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| JP2019512469A5 (ja) | ||
| CN101646650B (zh) | 亚型选择性氮杂二环烷烃衍生物 | |
| JP2019534327A5 (ja) | ||
| JP2007515479A5 (ja) | ||
| JP2005500354A5 (ja) |